Elsevier

Journal of Hepatology

Volume 65, Issue 1, July 2016, Pages 222-225
Journal of Hepatology

Public Health
Optimizing HCV treatment – Moving beyond the cost conundrum

https://doi.org/10.1016/j.jhep.2016.02.010Get rights and content

First page preview

First page preview
Click to open first page preview

References (41)

  • Daniel Lavanchy

    The global burden of hepatitis C

    Liver Int

    (2009)
  • R. Monina Klevens

    Evolving epidemiology of hepatitis C virus in the United States

    Clin Infect Dis

    (2012)
  • M.M. Denniston et al.

    Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001–2008

    Hepatology

    (2012)
  • B.D. Smith et al.

    Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965

    MMWR Recomm Rep

    (2012)
  • S.L. Chen et al.

    The natural history of hepatitis C virus (HCV) infection

    Int J Med Sci

    (2006)
  • L.B. Seeff

    The history of the “natural history” of hepatitis C (1968–2009)

    Liver Int

    (2009)
  • A.A. Butt et al.

    Effect of hepatitis C virus and its treatment on survival

    Hepatology

    (2009)
  • H.B. El-Serag et al.

    Risk factors for the rising rates of primary liver cancer in the United Stats

    Arch Intern Med

    (2000)
  • M.H. Lee et al.

    Chronic hepatitic C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study

    JID

    (2012)
  • Di Bisceglie A, Kuo A, Rustgi V, Sulkowski M. Virological Outcomes and Adherence to Treatment Algorithms in a...
  • Cited by (8)

    • Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population

      2021, Kidney International Reports
      Citation Excerpt :

      HCV-RNA polymerase chain reaction detection in dialysate may reflect viral RNA fragments, rather than the infectious virus.18 Some individuals could be members of more than 1 at-risk subpopulation at the time of starting dialysis.2,46,47 The cornerstone of HD facility transmission control is process safety, which includes the following: (i) the accurate and early identification of the HCV-infected reservoir using regularly scheduled HCV-RNA screening; (ii) the implementation and optimization of bedside HD safety processes via peer- and HD facility−driven leadership and public health and regional oversight; and (iii) capitalizing on technological support opportunities (Figure 2).

    • DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy

      2017, International Journal of Drug Policy
      Citation Excerpt :

      People who inject drugs may find it difficult to consistently attend the medical clinics that are the mainstay of standard of care (Papatheodoridis et al., 2014). Delaying treatment because of funding problems risks patients being lost to follow-up (Fox & McCombs, 2016). Creating the complex interventions necessary to eliminate HCV requires that well-designed cross-disciplinary programmes are put in place (Suther & Harries, 2016) using a variety of strategies to increase screening, testing and diagnosis (Brouard et al., 2015).

    • Age-dependent optimal policies for hepatitis C virus treatment

      2021, International Transactions in Operational Research
    • Treatment of early stage chronic hepatitis C virus infection

      2018, Expert Review of Clinical Pharmacology
    View all citing articles on Scopus
    View full text